Abbott India Q4 FY26 results:

📰 Abbott India Q4 FY26 Highlights Net Profit: ₹3.95B vs ₹3.7B YoY → +7% growth Revenue: ₹17B vs ₹16B YoY → +6% growth EBITDA: ₹4.8B vs ₹4.3B YoY → +12% growth EBITDA Margin: 28.09% vs 26.73% YoY → margin expansion of ~136 bps 🔎 Fundamentals Consistent growth in pharmaceutical sales and strong demand in chronic therapies. Margin expansion reflects cost efficiency and better product mix. Healthy balance sheet with strong cash flows. 🏥 Projects & Focus Areas Expansion in specialty drugs and nutritional products. Increased investment in R&D and innovation for new therapies. Strengthening presence in digital healthcare solutions. ⚠️ Risks Rising raw material costs could pressure margins. Regulatory compliance remains critical in pharma sector. Competition from domestic and global peers may impact market share. 📈 Outlook Strong pipeline of therapies supports future growth. Margin expansion trend is encouraging for investors. Abbott India remains a steady performer in pharma space with resilience against sector volatility.